Advertisement
Erratum Free access | 10.1172/JCI62856
Find articles by Agnihotri, S. in: JCI | PubMed | Google Scholar
Find articles by Gajadhar, A. in: JCI | PubMed | Google Scholar
Find articles by Ternamian, C. in: JCI | PubMed | Google Scholar
Find articles by Gorlia, T. in: JCI | PubMed | Google Scholar
Find articles by Diefes, K. in: JCI | PubMed | Google Scholar
Find articles by Mischel, P. in: JCI | PubMed | Google Scholar
Find articles by Kelly, J. in: JCI | PubMed | Google Scholar
Find articles by McGown, G. in: JCI | PubMed | Google Scholar
Find articles by Thorncroft, M. in: JCI | PubMed | Google Scholar
Find articles by Carlson, B. in: JCI | PubMed | Google Scholar
Find articles by Sarkaria, J. in: JCI | PubMed | Google Scholar
Find articles by Margison, G. in: JCI | PubMed | Google Scholar
Find articles by Aldape, K. in: JCI | PubMed | Google Scholar
Find articles by Hawkins, C. in: JCI | PubMed | Google Scholar
Find articles by Hegi, M. in: JCI | PubMed | Google Scholar
Find articles by Guha, A. in: JCI | PubMed | Google Scholar
Published February 1, 2012 - More info
Glioblastoma multiforme (GBM) is the most common and lethal of all gliomas. The current standard of care includes surgery followed by concomitant radiation and chemotherapy with the DNA alkylating agent temozolomide (TMZ). O6-methylguanine–DNA methyltransferase (MGMT) repairs the most cytotoxic of lesions generated by TMZ, O6-methylguanine. Methylation of the MGMT promoter in GBM correlates with increased therapeutic sensitivity to alkylating agent therapy. However, several aspects of TMZ sensitivity are not explained by MGMT promoter methylation. Here, we investigated our hypothesis that the base excision repair enzyme alkylpurine–DNA–N-glycosylase (APNG), which repairs the cytotoxic lesions N3-methyladenine and N7-methylguanine, may contribute to TMZ resistance. Silencing of APNG in established and primary TMZ-resistant GBM cell lines endogenously expressing MGMT and APNG attenuated repair of TMZ-induced DNA damage and enhanced apoptosis. Reintroducing expression of APNG in TMZ-sensitive GBM lines conferred resistance to TMZ in vitro and in orthotopic xenograft mouse models. In addition, resistance was enhanced with coexpression of MGMT. Evaluation of APNG protein levels in several clinical datasets demonstrated that in patients, high nuclear APNG expression correlated with poorer overall survival compared with patients lacking APNG expression. Loss of APNG expression in a subset of patients was also associated with increased APNG promoter methylation. Collectively, our data demonstrate that APNG contributes to TMZ resistance in GBM and may be useful in the diagnosis and treatment of the disease.
Sameer Agnihotri, Aaron S. Gajadhar, Christian Ternamian, Thierry Gorlia, Kristin L. Diefes, Paul S. Mischel, Joanna Kelly, Gail McGown, Mary Thorncroft, Brett L. Carlson, Jann N. Sarkaria, Geoffrey P. Margison, Kenneth Aldape, Cynthia Hawkins, Monika Hegi, Abhijit Guha
Original citation: J. Clin. Invest. 2012;122(1):253–266. doi:10.1172/JCI59334.
Citation for this erratum: J. Clin. Invest. 2012;122(2):782. doi:10.1172/JCI62856.
During the preparation of this manuscript, Figure 8B was inadvertently mislabeled. The correct figure appears below.
The JCI regrets the error.